Jason A. Mouabbi: 5 ILC Abstracts will be presented at ASCO24 as Poster Presentations on June 2nd

Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared on X:

“5 ILC Abstracts will be presented at ASCO24 as Poster Presentations on Sunday, June 2nd at 9:00 AM – 12:00 PM.

1. Racial disparities in presentation and survival for lobular breast cancer

Presenter: Simran Sandhu (University of Galway, Ireland); David W. Lim

Data: SEER database study with 38,769 ILC patients

Findings: Black women present with more advanced disease; Asian women are younger at diagnosis. 5-year overall survival for Black women is worse.

Takeaway: We must bridge the gaps in care for ILC patients across different races.

2. The multiomic tumor microenvironment landscape of ILC

Presenter: Jason A. Mouabbi (MD Anderson Cancer Center), BostonGeneCorp

Data: MxIF on 2,139,084 cells from FFPE whole-slide tissues

Findings: Detailed multiomic analysis reveals 40% of ILC samples are immune enriched (potential for immunotherapy) and 30% are highly vascularized (potential for anti-angiogenesis therapy).

Takeaway: Many ILC patients may benefit from immunotherapy or anti-angiogenesis regimens.

3. Neoadjuvant targeted therapy in HER2-mutant lobular breast cancer

Presenter: Laura Kennedy (Vanderbilt-Ingram Cancer Center); Ariella Hanker, Carlos Arteaga

Background: 10% of ILCs have HER2 (ERBB2) mutations, linked to ET resistance and worse prognosis.

Study: NCT05919108, Phase II trial for 30 patients with Stage I-III ILC and HER2 mutation, receiving letrozole plus neratinib for 6 months pre-surgery.

4. Transcriptomic analysis of cAMP/PKA/CREB signaling in ILC

Presenter: Susrutha Puthanmadhom Narayanan (Washington University School of Medicine); Steffi Oesterreich

Data: RNA-seq from three large breast cancer databases

Findings: Up-regulation of cAMP/PKA/CREB signaling in ILC compared to NST/IDC.

Takeaway: Unique signaling pathway in ILC could lead to novel therapeutic targets.